In part 2, Adam Colborn, JD, discussed federal health policy priorities, CMS fraud oversight, and how the midterm elections ...

One-year open-label MINT data show sustained MG-ADL and QMG score gains with inebilizumab, including in patients who switched from placebo.

Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight ...

Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial ...

The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.

Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve ...

An all-oral regimen is a meaningful advance in newly diagnosed AML, yet early monitoring needs, complex dosing, and patient readiness lead many clinicians to begin cycle 1 intravenously.